MSK1 activation in acute myeloid leukemia cells with FLT3 mutations
Authors:
- 1 April 2010
- journal article
- Published by Springer Nature in Leukemia
- Vol. 24 (5) , 1087-1090
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinibLeukemia & Lymphoma, 2009
- Mitogen- and Stress-Activated Kinase 1–Mediated Histone H3 Phosphorylation Is Crucial for Cell TransformationCancer Research, 2008
- Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell linesLeukemia, 2007
- After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignanciesBlood, 2005
- Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood, 2005
- Role of the p38 Mitogen-activated Protein Kinase Pathway in the Generation of the Effects of Imatinib Mesylate (STI571) in BCR-ABL-expressing CellsJournal of Biological Chemistry, 2004
- Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell lineLeukemia, 2002
- The nucleosomal response associated with immediate‐early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG‐14 kinaseThe EMBO Journal, 1999